TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

ConditionsSmall Cell Lung Cancer ( SCLC )Neuroendocrine Cancer Malignant Pleural Mesotheliomas (Mpm)Synovial Sarcomas

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorTreeline Biosciences, Inc.

About this trial

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TLN-499 in combination with venetoclax in participants with relapsed/refractory solid tumors.

Eligibility criteria

Qualifiers

Adults ≥18 years of age

Histologically confirmed relapsed/refractory SCLC, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma

Measurable disease per RECIST v1.1 or mRECIST

ECOG performance status 0-1

Disqualifiers

Active brain metastases

Major surgery or severe trauma within 4 weeks before first dose

Significant uncontrolled medical conditions preventing study participation

Use of prohibited concomitant medications

Trial design

Treatments tested in this trial

TLN-499
Venetoclax

Treatment groups

120 Participants

are divided into 1 treatment group

Sponsors and collaborators

Treeline Biosciences, Inc.

Lead sponsor

Source ClinicalTrials.gov